What is Confluence Discovery Technologies?
Founded in 2010 and headquartered in St. Louis, Missouri, Confluence Discovery Technologies operates as a specialized B2B pharmaceutical services firm. The company focuses on the high-stakes domain of drug discovery and development, providing essential scientific expertise and consulting to accelerate medical innovation. By maintaining a multi-site operational footprint, the firm bridges the gap between academic research and commercial pharmaceutical application, serving as a vital node in the health sector's R&D ecosystem. Its market position is defined by a deep integration of scientific rigor and strategic business development, allowing it to navigate the complexities of the modern drug pipeline.
How much funding has Confluence Discovery Technologies raised?
Confluence Discovery Technologies has raised a total of $11.2M across 3 funding rounds:
Series A
$4M
Unspecified
$2.4M
Private Equity
$4.8M
Series A (2012): $4M with participation from Helix Funds, DFJ Mercury, Missouri Technology, and BioGenerator
Unspecified (2015): $2.4M led by Missouri Technology, Epidarex Capital, BioGenerator, St Louis Arch Angels, and Mercury Fund
Private Equity (2016): $4.8M, investors not publicly disclosed
Key Investors in Confluence Discovery Technologies
BioGenerator
Based in St. Louis, Missouri, BioGenerator creates and grows innovative companies through its two complementary approaches, investing through BioGenerator Ventures and comprehensive startup support through BioGenerator Labs.
Missouri Technology
The Missouri Technology Corporation is a public-private partnership that targets the life sciences and technology sectors, offering venture capital investments and grants to foster regional innovation.
Epidarex Capital
Epidarex is a transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs, utilizing deep scientific networks to create exceptional value.
What's next for Confluence Discovery Technologies?
With the recent influx of capital, Confluence Discovery Technologies is well-positioned to expand its proprietary research platforms and enhance its service delivery capabilities. The strategic focus will likely shift toward scaling its laboratory operations and deepening its bench of scientific talent to meet the growing demand for outsourced drug discovery solutions. As the company matures, the emphasis will remain on fostering high-value partnerships and driving innovation in precision medicine, ensuring that its technological assets remain at the forefront of the pharmaceutical industry's evolving requirements.
See full Confluence Discovery Technologies company page
